286 results on '"Foucher, Juliette"'
Search Results
2. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort
3. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
4. The usage of population and disease registries as pre-screening tools for clinical trials, a systematic review
5. ECAS correlation with metabolic alterations on FDG-PET imaging in ALS
6. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
7. Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease
8. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD
9. A randomized, double‐blind, placebo‐controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis.
10. Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS)
11. Liver stiffness measurements with a new point-of-care device, hepatoscope, using two-dimensional transient elastography showed both very good reproducibility and correlation to fibroscan
12. HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort
13. Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program
14. Two-dimensional versus one-dimensional transient elastography: benefits of ultrasound imaging-based processing for liver stiffness measurements
15. Quantitative ultrasound for liver steatosis assessment: benefits of measurements over a large two-dimensional region of interest on the performance of image-brightness-based parameters
16. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort
17. Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
18. Liver and spleen elastography using supersonic shear imaging for the non-invasive diagnosis of cirrhosis severity and oesophageal varices
19. MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity
20. International network for ALS research and care (INARC)
21. Repeated noninvasive liver biopsy surrogate LIVERFASt correlates with BMI and liver enzyme improvements
22. Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide
23. Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings
24. Hepatitis C virus prevention and care for drug injectors: the French approach
25. Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe
26. Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients
27. Screening for liver fibrosis by using FibroScan® and FibroTest in patients with diabetes
28. Long‐term prognosis of patients with metabolic (dysfunction)‐associated fatty liver disease by non‐invasive methods
29. Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use
30. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease
31. Liver stiffness measurements for evaluation of central venous pressure in congenital heart diseases
32. 76-OR: LIVERFASt Has Similar Performance to Liver Biopsy for the Screening of NASH Fibrosis in T2DM
33. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort
34. Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort)
35. SAT-184 - Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program
36. WED-469 - Quantitative ultrasound for liver steatosis assessment: benefits of measurements over a large two-dimensional region of interest on the performance of image-brightness-based parameters
37. WED-453 - Two-dimensional versus one-dimensional transient elastography: benefits of ultrasound imaging-based processing for liver stiffness measurements
38. SAT-505 - Liver stiffness measurements with a new point-of-care device, hepatoscope, using two-dimensional transient elastography showed both very good reproducibility and correlation to fibroscan
39. OS-066 - HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort
40. Comment gérer les comorbidités en hépatologie ? Vers une médecine plus globale
41. Evolution of Noninvasive Tests of Liver Fibrosis Is Associated With Prognosis in Patients With Chronic Hepatitis C
42. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort
43. Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus
44. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: Long-term follow-up of 196 patients (4535 patient-years)
45. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI)
46. The evolution of liver stiffness predicts 4-year survival of patients with chronic hepatitis C: 1013
47. Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use.
48. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography
49. Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness
50. Neutralizing Antibodies to Interferon-α and Circulating Interferon in Patients With Chronic Hepatitis C Non-Responding to Pegylated Interferon Plus Ribavirin Re-Treated by Pegylated Interferon-α-2A and Ribavirin (Anrs Hc16 Gammatri Substudy*)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.